SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Clinical Data Inc.
 Public ReplyPrvt ReplyMark as Last ReadFileNext 10PreviousNext  
From: Mike McFarland2/6/2006 6:10:28 PM
  Read Replies (1) of 39
 
NCT00285376 Official Title: A Randomized, Double-Blind,
Placebo Controlled Study Assessing the Efficacy and Safety
of Vilazodone and Discovering Genetic Markers Associated
With Response in Patients With Major Depressive Disorder

Further study details as provided by Genaissance Pharmaceuticals:

Expected Total Enrollment: 408
Study start: February 2006; Expected completion: May 2007
Last follow-up: January 2007; Data entry closure: February 2007

This randomized, double-blind, placebo-controlled, multicenter, 8-week, clinical trial is designed to assess the efficacy and safety of vilazodone and to discover genetic markers of treatment response associated with vilazodone use in adult patients diagnosed with MDD by the DSM-IV-TR criteria. This study will enroll approximately 408 patients.

clinicaltrials.gov

For background, just search Vilazodone here on SI

Here is the CLDA Press Release
clda.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFileNext 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News